{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:06:47Z","timestamp":1790719607112,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13318-025-00972-1","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T11:37:28Z","timestamp":1763379448000},"page":"61-73","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Impact of Fluvoxamine on Clozapine and Norclozapine Serum Concentrations"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6921-3846","authenticated-orcid":false,"given":"G.","family":"van Weringh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. J.","family":"de Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"de Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Touw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. B.","family":"de Koning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"issue":"3","key":"972_CR1","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","volume":"174","author":"OD Howes","year":"2017","unstructured":"Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174(3):216\u201329.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"972_CR2","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789\u201396.","journal-title":"Arch Gen Psychiatry"},{"issue":"1\u201302","key":"972_CR3","first-page":"9","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1\u201302):9\u201362.","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"972_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/01.jcp.0000106221.36344.4d","volume":"24","author":"A Rostami-Hodjegan","year":"2004","unstructured":"Rostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol. 2004;24(1):70\u20138.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"972_CR5","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/FTD.0b013e31819c7037","volume":"31","author":"W Ng","year":"2009","unstructured":"Ng W, Uchida H, Ismail Z, Mamo DC, Rajji TK, Remington G, et al. Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. Ther Drug Monit. 2009;31(3):360\u20136.","journal-title":"Ther Drug Monit"},{"key":"972_CR6","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.2147\/NDT.S163839","volume":"14","author":"M Mayerova","year":"2018","unstructured":"Mayerova M, Ustohal L, Jarkovsky J, Pivnicka J, Kasparek T, Ceskova E. Influence of dose, gender, and cigarette smoking on clozapine plasma concentrations. Neuropsychiatr Dis Treat. 2018;14:1535\u201343.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"6","key":"972_CR7","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/JCP.0000000000001762","volume":"43","author":"RJ Flanagan","year":"2023","unstructured":"Flanagan RJ, Hunter S, Obee SJ. Effect of cigarette smoking on clozapine dose and on plasma clozapine and N-desmethylclozapine (norclozapine) concentrations in clinical practice. J Clin Psychopharmacol. 2023;43(6):514\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"972_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/acps.13264","volume":"143","author":"Y Yada","year":"2020","unstructured":"Yada Y, Kitagawa K, Sakamoto S, Ozawa A, Nakada A, Kashiwagi H, et al. The relationship between plasma clozapine concentration and clinical outcome: a cross-sectional study. Acta Psychiatr Scand. 2020;143(3):227\u201337.","journal-title":"Acta Psychiatr Scand"},{"issue":"8","key":"972_CR9","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1177\/00912700122010717","volume":"41","author":"OV Olesen","year":"2001","unstructured":"Olesen OV, Linnet K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol. 2001;41(8):823\u201332.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"972_CR10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1046\/j.1365-2125.1997.t01-1-00605.x","volume":"44","author":"B Eiermann","year":"1997","unstructured":"Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol. 1997;44(5):439\u201346.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"972_CR11","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/00007691-199408000-00006","volume":"16","author":"M Jerling","year":"1994","unstructured":"Jerling M, Lindstr\u00f6m L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit. 1994;16(4):368\u201374.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"972_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/00004714-199802000-00002","volume":"18","author":"H Wetzel","year":"1998","unstructured":"Wetzel H, Anghelescu I, Szegedi A, Wiesner J, Weigmann H, H\u00e4rter S, et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol. 1998;18(1):2\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"972_CR13","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1097\/00004714-200012000-00024","volume":"20","author":"M Fabrazzo","year":"2000","unstructured":"Fabrazzo M, La Pia S, Monteleone P, Mennella R, Esposito G, Pinto A, et al. Fluvoxamine increases plasma and urinary levels of clozapine and its major metabolites in a time- and dose-dependent manner. J Clin Psychopharmacol. 2000;20(6):708\u201310.","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"972_CR14","doi-asserted-by":"publisher","first-page":"594","DOI":"10.4088\/JCP.v61n0809","volume":"61","author":"ML Lu","year":"2000","unstructured":"Lu ML, Lane HY, Chen KP, Jann MW, Su MH, Chang WH. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry. 2000;61(8):594\u20139.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"972_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/00004714-200002000-00007","volume":"20","author":"OV Olesen","year":"2000","unstructured":"Olesen OV, Linnet K. Fluvoxamine-clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism. J Clin Psychopharmacol. 2000;20(1):35\u201342.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"972_CR16","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.mehy.2012.12.024","volume":"80","author":"N Legare","year":"2013","unstructured":"Legare N, Gregoire CA, De Benedictis L, Dumais A. Increasing the clozapine: norclozapine ratio with co-administration of fluvoxamine to enhance efficacy and minimize side effects of clozapine therapy. Med Hypotheses. 2013;80(6):689\u201391.","journal-title":"Med Hypotheses"},{"issue":"5","key":"972_CR17","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00213-015-4161-1","volume":"233","author":"C Polcwiartek","year":"2016","unstructured":"Polcwiartek C, Nielsen J. The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review. Psychopharmacology. 2016;233(5):741\u201350.","journal-title":"Psychopharmacology"},{"issue":"2","key":"972_CR18","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/bcp.14992","volume":"88","author":"NT Jessurun","year":"2022","unstructured":"Jessurun NT, Derijks HJ, van Marum RJ, Jongkind A, Giraud EL, van Puijenbroek EP, et al. Body weight gain in clozapine-treated patients: is norclozapine the culprit? Br J Clin Pharmacol. 2022;88(2):853\u20137.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"972_CR19","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/JCP.0000000000001245","volume":"40","author":"W Zheng","year":"2020","unstructured":"Zheng W, Xiang YQ, Cai DB, Yang XH, Zhang L, Zheng W, et al. Adjunctive fluvoxamine for schizophrenia: a meta-analysis of randomized double-blind, placebo-controlled trials. J Clin Psychopharmacol. 2020;40(4):386\u201390.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"972_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1055\/a-1625-6388","volume":"55","author":"J de Leon","year":"2022","unstructured":"de Leon J, Schoretsanitis G, Smith RL, Molden E, Solismaa A, Sepp\u00e4l\u00e4 N, et al. An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels. Pharmacopsychiatry. 2022;55(2):73\u201386.","journal-title":"Pharmacopsychiatry"},{"key":"972_CR21","unstructured":"Rehabilitation for adults with complex psychosis\u2014NICE Guideline. www.nice.org.uk\/guidance\/ng181. Accessed June 2025."},{"issue":"3","key":"972_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s12508-019-0213-y","volume":"97","author":"R Scholte","year":"2019","unstructured":"Scholte R, Kranendonk E, Paardekooper M, Ploem C. Hergebruik van pati\u00ebntgegevens voor wetenschappelijk onderzoek: op weg naar eenduidige spelregels. Tijdschrift voor gezondheidswetenschappen. 2019;97(3):55\u20138.","journal-title":"Tijdschrift voor gezondheidswetenschappen"},{"key":"972_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.schres.2019.05.033","volume":"210","author":"M Augustin","year":"2019","unstructured":"Augustin M, Schoretsanitis G, Pfeifer P, Grunder G, Liebe C, Paulzen M. Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations. Schizophr Res. 2019;210:143\u20138.","journal-title":"Schizophr Res"},{"issue":"6","key":"972_CR24","first-page":"923","volume":"29","author":"G Schaber","year":"2001","unstructured":"Schaber G, Wiatr G, Wachsmuth H, Dachtler M, Albert K, Gaertner I, et al. Isolation and identification of clozapine metabolites in patient urine. Drug Metab Dispos. 2001;29(6):923\u201331.","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"972_CR25","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1124\/dmd.120.000350","volume":"49","author":"JL Beers","year":"2021","unstructured":"Beers JL, Fu D, Jackson KD. Cytochrome P450-catalyzed metabolism of cannabidiol to the active metabolite 7-hydroxy-cannabidiol. Drug Metab Dispos. 2021;49(10):882\u201391.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"972_CR26","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1124\/dmd.112.050278","volume":"41","author":"CM Loi","year":"2013","unstructured":"Loi CM, Smith DA, Dalvie D. Which metabolites circulate? Drug Metab Dispos. 2013;41(5):933\u201351.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"972_CR27","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1046\/j.1365-2125.1998.00822.x","volume":"46","author":"G Schaber","year":"1998","unstructured":"Schaber G, Stevens I, Gaertner HJ, Dietz K, Breyer-Pfaff U. Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. Br J Clin Pharmacol. 1998;46(5):453\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"972_CR28","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1124\/dmd.105.008672","volume":"34","author":"MF Paine","year":"2006","unstructured":"Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 \u201cpie.\u201d Drug Metab Dispos. 2006;34(5):880\u20136.","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"972_CR29","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40263-024-01092-1","volume":"38","author":"O Albitar","year":"2024","unstructured":"Albitar O, Harun SN, Sheikh Ghadzi SM. Semi-physiological pharmacokinetic model of clozapine and norclozapine in healthy, non-smoking volunteers: the impact of race and genetics. CNS Drugs. 2024;38(7):571\u201381.","journal-title":"CNS Drugs"},{"issue":"7","key":"972_CR30","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1177\/0091270004266621","volume":"44","author":"CY Wang","year":"2004","unstructured":"Wang CY, Zhang ZJ, Li WB, Zhai YM, Cai ZJ, Weng YZ, et al. The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers. J Clin Pharmacol. 2004;44(7):785\u201392.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"972_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1067\/mcp.2002.121788","volume":"71","author":"M Christensen","year":"2002","unstructured":"Christensen M, Tybring G, Mihara K, Yasui-Furokori N, Carrillo JA, Ramos SI, et al. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther. 2002;71(3):141\u201352.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"972_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/acps.12742","volume":"136","author":"CJ Bachmann","year":"2017","unstructured":"Bachmann CJ, Aagaard L, Bernardo M, Brandt L, Cartabia M, Clavenna A, et al. International trends in clozapine use: a study in 17 countries. Acta Psychiatr Scand. 2017;136(1):37\u201351.","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"972_CR33","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.mehy.2013.11.043","volume":"82","author":"RM Procyshyn","year":"2014","unstructured":"Procyshyn RM, Vila-Rodriguez F, Honer WG, Barr AM. Clozapine administered once versus twice daily: does it make a difference? Med Hypotheses. 2014;82(2):225\u20138.","journal-title":"Med Hypotheses"},{"issue":"3","key":"972_CR34","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1046\/j.1365-2125.1998.00670.x","volume":"45","author":"O Spigset","year":"1998","unstructured":"Spigset O, Granberg K, H\u00e4gg S, S\u00f6derstr\u00f6m E, Dahlqvist R. Non-linear fluvoxamine disposition. Br J Clin Pharmacol. 1998;45(3):257\u201363.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"972_CR35","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/00007691-199808000-00016","volume":"20","author":"S H\u00e4rtter","year":"1998","unstructured":"H\u00e4rtter S, Wetzel H, Hammes E, Torkzadeh M, Hiemke C. Nonlinear pharmacokinetics of fluvoxamine and gender differences. Ther Drug Monit. 1998;20(4):446\u20139.","journal-title":"Ther Drug Monit"},{"issue":"2\u20133","key":"972_CR36","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.schres.2012.08.018","volume":"141","author":"KJ Ronaldson","year":"2012","unstructured":"Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, Wolfe R, McNeil JJ. Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study. Schizophr Res. 2012;141(2\u20133):173\u20138.","journal-title":"Schizophr Res"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00972-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-025-00972-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00972-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T15:38:48Z","timestamp":1771861128000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-025-00972-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["972"],"URL":"https:\/\/doi.org\/10.1007\/s13318-025-00972-1","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Figure 3 caption updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was reviewed by the Medical research Ethics Committees United (MEC-U, study-reference W17.058)","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Data will be made available on reasonable request","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"GvW: conceptualization, data curation, formal analysis, investigation, writing-original draft, writing-review and editing. HdH: conceptualization, writing\u2014original draft, writing-review and editing. LdH: writing\u2014review and editing. DT: conceptualization, supervision, writing\u2014review and editing. MdK: conceptualization, supervision, writing\u2014review and editing.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}